AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2014
Jul 2, 2014
30591_dirs_2014-07-02_dee60732-828e-4d28-97bc-bbddacafd205.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2014-07-01
Reporting Person: O'NEIL PATRICK R. (SVP, Legal & General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-07-01 | Common Stock | J | 403 | $30.2005 | Acquired | 3753 | Direct |
| 2014-07-01 | Common Stock | M | 1500 | $10.29 | Acquired | 5253 | Direct |
| 2014-07-01 | Common Stock | S | 1500 | $35.3333 | Disposed | 3753 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-07-01 | Employee Stock Option (right to buy) | $10.29 | M | 1500 | Disposed | 2018-01-02 | Common Stock (1500) | Direct |
Footnotes
F1: Reporting 403 shares acquired under the Isis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on July 1, 2014. These 403 shares may not be sold until January 2, 2015.
F2: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plans adopted by the reporting person on 1/2/14.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.20 to $35.50, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4: Grant of 1/3/2011 to reporting person of stock options under the Isis Pharmacueticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/3/2012. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 5,750 shares per year. Following this transaction, the option was exercisable as to 5,628 on 7/1/2014.